Reduced mortality during the COVID-19 outbreak in Japan, 2020: a two-stage interrupted time-series design.


Journal

International journal of epidemiology
ISSN: 1464-3685
Titre abrégé: Int J Epidemiol
Pays: England
ID NLM: 7802871

Informations de publication

Date de publication:
18 02 2022
Historique:
received: 30 03 2021
accepted: 15 09 2021
pubmed: 1 11 2021
medline: 24 2 2022
entrez: 31 10 2021
Statut: ppublish

Résumé

Coronavirus disease 2019 (COVID-19) continues to be a major global health burden. This study aims to estimate the all-cause excess mortality occurring in the COVID-19 outbreak in Japan, 2020, by sex and age group. Daily time series of mortality for the period January 2015-December 2020 in all 47 prefectures of Japan were obtained from the Ministry of Health, Labour and Welfare, Japan. A two-stage interrupted time-series design was used to calculate excess mortality. In the first stage, we estimated excess mortality by prefecture using quasi-Poisson regression models in combination with distributed lag non-linear models, adjusting for seasonal and long-term variations, weather conditions and influenza activity. In the second stage, we used a random-effects multivariate meta-analysis to synthesize prefecture-specific estimates at the nationwide level. In 2020, we estimated an all-cause excess mortality of -20 982 deaths [95% empirical confidence intervals (eCI): -38 367 to -5472] in Japan, which corresponded to a percentage excess of -1.7% (95% eCI: -3.1 to -0.5) relative to the expected value. Reduced deaths were observed for both sexes and in all age groups except those aged <60 and 70-79 years. All-cause mortality during the COVID-19 outbreak in Japan in 2020 was decreased compared with a historical baseline. Further evaluation of cause-specific excess mortality is warranted.

Sections du résumé

BACKGROUND
Coronavirus disease 2019 (COVID-19) continues to be a major global health burden. This study aims to estimate the all-cause excess mortality occurring in the COVID-19 outbreak in Japan, 2020, by sex and age group.
METHODS
Daily time series of mortality for the period January 2015-December 2020 in all 47 prefectures of Japan were obtained from the Ministry of Health, Labour and Welfare, Japan. A two-stage interrupted time-series design was used to calculate excess mortality. In the first stage, we estimated excess mortality by prefecture using quasi-Poisson regression models in combination with distributed lag non-linear models, adjusting for seasonal and long-term variations, weather conditions and influenza activity. In the second stage, we used a random-effects multivariate meta-analysis to synthesize prefecture-specific estimates at the nationwide level.
RESULTS
In 2020, we estimated an all-cause excess mortality of -20 982 deaths [95% empirical confidence intervals (eCI): -38 367 to -5472] in Japan, which corresponded to a percentage excess of -1.7% (95% eCI: -3.1 to -0.5) relative to the expected value. Reduced deaths were observed for both sexes and in all age groups except those aged <60 and 70-79 years.
CONCLUSIONS
All-cause mortality during the COVID-19 outbreak in Japan in 2020 was decreased compared with a historical baseline. Further evaluation of cause-specific excess mortality is warranted.

Identifiants

pubmed: 34718594
pii: 6413683
doi: 10.1093/ije/dyab216
pmc: PMC8856001
doi:

Types de publication

Journal Article Meta-Analysis Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

75-84

Subventions

Organisme : Ministry of Health, Labour and Welfare
ID : JPMH20HA2007
Organisme : Japan Society for the Promotion of Science (JSPS) KAKENHI
ID : JP18K11666
Organisme : Japan Society for the Promotion of Science
Organisme : KAKENHI
ID : JP18K11666

Informations de copyright

© The Author(s) 2021. Published by Oxford University Press on behalf of the International Epidemiological Association.

Références

Int J Epidemiol. 2013 Aug;42(4):1187-95
pubmed: 23760528
J Epidemiol Community Health. 2021 Aug;75(8):735-740
pubmed: 33468602
Travel Med Infect Dis. 2020 May - Jun;35:101661
pubmed: 32272198
Stat Med. 2014 Feb 28;33(5):881-99
pubmed: 24027094
JAMA Intern Med. 2021 May 1;181(5):705-707
pubmed: 33346804
Inj Epidemiol. 2021 Jan 18;7(1):66
pubmed: 33256821
BMJ. 2021 May 19;373:n1137
pubmed: 34011491
Heart. 2016 Jul 1;102(13):987-9
pubmed: 27091845
MMWR Morb Mortal Wkly Rep. 2020 Oct 23;69(42):1522-1527
pubmed: 33090978
Am J Geriatr Psychiatry. 2020 Dec;28(12):1233-1244
pubmed: 32919873
Ageing Res Rev. 2015 Jul;22:39-57
pubmed: 25956016
Science. 2016 Apr 22;352(6284):aaf1098
pubmed: 27102489
Epidemiology. 2019 May;30(3):321-329
pubmed: 30829832
BMJ. 2016 Oct 13;355:i5170
pubmed: 27737834
JAMA Intern Med. 2020 Oct 1;180(10):1336-1344
pubmed: 32609310
Cell Discov. 2020 Feb 24;6:11
pubmed: 32133153
J Epidemiol. 2021 Jan 5;31(1):90-92
pubmed: 33132284
Lancet. 2015 Jul 25;386(9991):369-75
pubmed: 26003380
N Engl J Med. 2020 Apr 30;382(18):1708-1720
pubmed: 32109013
Euro Surveill. 2021 Jan;26(2):
pubmed: 33446304
JAMA Netw Open. 2021 Feb 1;4(2):e2037378
pubmed: 33528554
Int J Epidemiol. 2021 Jan 23;49(6):1909-1917
pubmed: 33053172
Eur Rev Aging Phys Act. 2021 Mar 1;18(1):5
pubmed: 33648448
Lancet Planet Health. 2017 Dec;1(9):e360-e367
pubmed: 29276803
Environ Res. 2015 Oct;142:319-27
pubmed: 26188633
Stat Med. 2012 Dec 20;31(29):3821-39
pubmed: 22807043
Emerg Infect Dis. 2021 Mar;27(3):789-795
pubmed: 33622468
QJM. 2020 Aug 1;113(8):551-555
pubmed: 32573730
EMBO Mol Med. 2020 May 8;12(5):e12481
pubmed: 32275804
Pharm Res. 2020 Oct 6;37(11):212
pubmed: 33025261
Emerg Infect Dis. 2021 Feb;27(2):411-420
pubmed: 33395381
Heart. 2016 Jul 1;102(13):1009-16
pubmed: 27091846
J Am Acad Child Adolesc Psychiatry. 2020 Nov;59(11):1218-1239.e3
pubmed: 32504808
Eur J Clin Microbiol Infect Dis. 2021 May;40(5):905-919
pubmed: 33389262
BMC Med Res Methodol. 2014 Apr 23;14:55
pubmed: 24758509
Stat Med. 2019 Dec 20;38(29):5429-5444
pubmed: 31647135
Trop Med Health. 2021 May 13;49(1):38
pubmed: 33985579
JAMA. 2021 Feb 23;325(8):785-787
pubmed: 33325994
Eur Psychiatry. 2020 Sep 28;63(1):e87
pubmed: 32981568
Lancet Infect Dis. 2020 Oct;20(10):1123
pubmed: 32305069
N Engl J Med. 2020 Aug 6;383(6):510-512
pubmed: 32283003
Perspect Psychol Sci. 2015 Mar;10(2):227-37
pubmed: 25910392
Int J Environ Res Public Health. 2021 Mar 22;18(6):
pubmed: 33809955
JAMA. 2020 May 19;323(19):1969-1971
pubmed: 32275293

Auteurs

Daisuke Onozuka (D)

Department of Medical Informatics and Clinical Epidemiology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan.

Yuta Tanoue (Y)

Institute for Business and Finance, Waseda University, Tokyo, Japan.
Department of Health Policy and Management, School of Medicine, Keio University, Tokyo, Japan.

Shuhei Nomura (S)

Department of Health Policy and Management, School of Medicine, Keio University, Tokyo, Japan.
Department of Global Health Policy, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.

Takayuki Kawashima (T)

Department of Health Policy and Management, School of Medicine, Keio University, Tokyo, Japan.
Department of Mathematical and Computing Science, Tokyo Institute of Technology, Tokyo, Japan.

Daisuke Yoneoka (D)

Department of Health Policy and Management, School of Medicine, Keio University, Tokyo, Japan.
Department of Global Health Policy, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Graduate School of Public Health, St. Luke's International University, Tokyo, Japan.

Akifumi Eguchi (A)

Department of Health Policy and Management, School of Medicine, Keio University, Tokyo, Japan.
Department of Sustainable Health Science, Center for Preventive Medical Sciences, Chiba University, Chiba, Japan.

Chris Fook Sheng Ng (CFS)

School of Tropical Medicine and Global Health, Nagasaki University, Nagasaki, Japan.

Kentaro Matsuura (K)

Department of Management Science, Graduate School of Engineering, Tokyo University of Science, Tokyo, Japan.
HOXO-M Inc., Tokyo, Japan.

Shoi Shi (S)

Department of Systems Pharmacology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Laboratory for Synthetic Biology, RIKEN Center for Biosystems Dynamics Research, Osaka, Japan.

Koji Makiyama (K)

HOXO-M Inc., Tokyo, Japan.

Shinya Uryu (S)

Center for Environmental Biology and Ecosystem Studies, National Institute for Environmental Studies (NIES), Tokyo, Japan.

Yumi Kawamura (Y)

RIKEN Center for Sustainable Resource Science, Saitama, Japan.

Shinichi Takayanagi (S)

HOXO-M Inc., Tokyo, Japan.

Stuart Gilmour (S)

Graduate School of Public Health, St. Luke's International University, Tokyo, Japan.

Takehiko I Hayashi (TI)

Center for Health and Environmental Risk Research, National Institute for Environmental Studies, Ibaraki, Japan.

Hiroaki Miyata (H)

Department of Health Policy and Management, School of Medicine, Keio University, Tokyo, Japan.

Francesco Sera (F)

Department of Statistics, Computer Science and Applications 'G. Parenti', University of Florence, Florence, Italy.

Tomimasa Sunagawa (T)

Infectious Disease Surveillance Center, the National Institute of Infectious Diseases, Tokyo, Japan.

Takuri Takahashi (T)

Infectious Disease Surveillance Center, the National Institute of Infectious Diseases, Tokyo, Japan.

Yuuki Tsuchihashi (Y)

Infectious Disease Surveillance Center, the National Institute of Infectious Diseases, Tokyo, Japan.

Yusuke Kobayashi (Y)

Infectious Disease Surveillance Center, the National Institute of Infectious Diseases, Tokyo, Japan.

Yuzo Arima (Y)

Infectious Disease Surveillance Center, the National Institute of Infectious Diseases, Tokyo, Japan.

Kazuhiko Kanou (K)

Infectious Disease Surveillance Center, the National Institute of Infectious Diseases, Tokyo, Japan.

Motoi Suzuki (M)

Infectious Disease Surveillance Center, the National Institute of Infectious Diseases, Tokyo, Japan.

Masahiro Hashizume (M)

Department of Global Health Policy, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH